Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

INTRODUCTION: Risankizumab has been approved for the treatment of moderate-to-severe plaque psoriasis; however, real-life data are limited. Our objectives were to evaluate the effectiveness and safety of risankizumab and its impact on the quality of life of patients with psoriasis in a real-world se...

Descripción completa

Detalles Bibliográficos
Autores principales: Gkalpakiotis, Spyridon, Cetkovska, Petra, Arenberger, Petr, Dolezal, Tomas, Arenbergerova, Monika, Velackova, Barbora, Fialova, Jorga, Kojanova, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179080/
https://www.ncbi.nlm.nih.gov/pubmed/34089479
http://dx.doi.org/10.1007/s13555-021-00556-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179080/
https://www.ncbi.nlm.nih.gov/pubmed/34089479
http://dx.doi.org/10.1007/s13555-021-00556-2

Ejemplares similares